CAMBRIDGE, Mass. (AP) -- Javelin Pharmaceuticals Inc. said Monday its licensee for the pain treatment Dyloject has withdrawn all batches of the drug from the United Kingdom and shares tumbled 25 percent.
The licensee, Therabel Pharma UK Ltd., notified the company of the presence of a "white particulate matter" in some vials of Dyloject. Javelin, said Therabel was cooperating fully with The Medicines and Healthcare Products Regulatory Agency, with assistance from Javelin.
Javelin is the subject of a $145-million tender offer from drug and medical device maker Hospira Inc.
Shares of Javelin, based in Cambridge, Mass., fell 45 cents to $1.35 in Monday morning trading.
